'Brain Disease Analysis' Neurofit Shares Open Innovation Case with Roche Diagnostics

Neurofit, a specialized company in brain disease imaging artificial intelligence (AI) solutions, announced on the 13th that it recently presented a successful case of global healthcare collaboration at Bio Korea 2024 held at COEX in Gangnam-gu, Seoul.

Bin Jun-gil, CEO of Neurofit, attended the MedTech Open Innovation briefing session hosted by the Korea Health Industry Development Institute and Roche Diagnostics, held in conjunction with Bio Korea 2024, as a speaker to share the collaboration case between Roche Diagnostics and Neurofit.

Neurofit signed an agreement last September for the Korea Health Industry Development Institute’s Global Research Cooperation Support Project and has been building an open innovation partnership with Roche Diagnostics. Through this project, Neurofit was selected as a participating company in the global startup innovation program, 'Startup Crisper APAC 2023.' With support from Roche Diagnostics’ Asia-Pacific regional headquarters, Neurofit conducted research and development on brain imaging analysis technology and engaged in collaborative activities to create business synergies related to Alzheimer’s cerebrospinal fluid (CSF) testing with Roche Diagnostics. Neurofit focused its R&D efforts on technology that predicts the risk of amyloid-beta protein, known as the causative agent of Alzheimer’s dementia, based on brain magnetic resonance imaging (MRI) analysis within the program.

CEO Bin said, “Through last year’s project with the Korea Health Industry Development Institute, we had the opportunity to collaborate with Roche Diagnostics, a leader in the diagnostics field, and have created a successful global cooperation case. We are dedicating ourselves to business collaboration for the early diagnosis of Alzheimer’s dementia by leveraging Neurofit’s AI-based brain imaging analysis technology to generate synergy with Roche Diagnostics’ CSF testing.”